Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug

The FDA denied two Citizen Petitions -- including one filed by Eisai and Arena Pharmaceuticals  ( ARNA) -- requesting additional New Chemical Entity (NCE) market exclusivity to make up for the commercial launch delay caused by need to wait for DEA scheduling.

Eisai and Arena received FDA approval to market the weight-loss drug Belviq on June 27, 2012. The approval data also triggered the start of the drug's five-year market exclusivity as a New Chemical Entity (NCE), per FDA regulations. However, FDA would not allow Eisai and Arena to start selling Belviq until DEA scheduling was completed, given the drug's abuse potential. The final order for DEA scheduling was filed on June 7, 2013, meaning Eisai and Arena lost almost one year of market exclusivity.

In a Citizen Petition, Eisai argued the clock on NCE market exclusivity should start no the date the drug can be marketed, not the formal approval date. 

In response, the FDA said no.

Here's a link to the FDA's ruling on the Citzen Petitions.

FDA Law Blog has also posted on the matter. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says